Timothy Endy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Timothy Endy has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Alison A. Bettis
Coalition for Epidemic Preparedness Innovations, Askekroken 11, 0277 Oslo, Norway
1 shared publication - Byoung-Shik Shim
International Vaccine Institute, Seoul, Republic of Korea.
1 shared publication - Gene Malin
Coalition for Epidemic Preparedness Innovations, Askekroken 11, 0277 Oslo, Norway
1 shared publication - Hitoshi Sasaki
Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan
1 shared publication - Javier Castillo-Olivares
Laboratory of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge, Cambridge CB3 0ES, UK
1 shared publication - Jimmy D. Gollihar
Systems, Synthetic, and Physical Biology, Rice University
1 shared publication
Latest Publications
- Open Access
CEPI Workshop Report: Applying Disease X Vaccine Library and Knowledge Base Approaches to Severe Fever with Thrombocytopenia Syndrome (SFTS)
On 9–10 December 2025, the Coalition for Epidemic Preparedness Innovations (CEPI) and the International Vaccine Institute (IVI) convened a workshop in Seoul under CEPI’s Disease X Program. The primary objective was to identify existing gaps needing to be filled and streamline vaccine development and preparedness for Severe Fever with Thrombocytopenia Syndrome (SFTS). CEPI’s partners and experts discussed a multifaceted agenda, ranging from understanding the evolving epidemiology to the refinement of animal models and immunological assay harmonization. Key outcomes included the refinement of Target Product Profiles (TPPs) specifying use cases for both peacetime and outbreak contexts, alongside a recommendation for a core immunoassay panel aimed at harmonizing evaluation frameworks and mitigating the challenges posed by low SFTS prevalence. Integration of the One Health approach emerged as a critical strategy for SFTS prevention, complemented by proactive regulatory engagement to compress vaccine development timelines. This report summarizes these key insights from the workshop, delineating a strategic framework for delivering safe, effective, and accessible vaccines for SFTS and broader Disease X threats.
Open AccessCEPI Workshop Report: Applying Disease X Vaccine Library and Knowledge Base Approaches to Severe Fever with Thrombocytopenia Syndrome (SFTS)
On 9–10 December 2025, the Coalition for Epidemic Preparedness Innovations (CEPI) and the International Vaccine Institute (IVI) convened a workshop in Seoul under CEPI’s Disease X Program. The primary objective was to identify existing gaps needing to be filled and streamline vaccine development and preparedness for Severe Fever with Thrombocytopenia Syndrome (SFTS). CEPI’s partners and experts discussed a multifaceted agenda, ranging from understanding the evolving epidemiology to the refinement of animal models and immunological assay harmonization. Key outcomes included the refinement of Target Product Profiles (TPPs) specifying use cases for both peacetime and outbreak contexts, alongside a recommendation for a core immunoassay panel aimed at harmonizing evaluation frameworks and mitigating the challenges posed by low SFTS prevalence. Integration of the One Health approach emerged as a critical strategy for SFTS prevention, complemented by proactive regulatory engagement to compress vaccine development timelines. This report summarizes these key insights from the workshop, delineating a strategic framework for delivering safe, effective, and accessible vaccines for SFTS and broader Disease X threats.